JAK Inhibitors for Treatment of SAPHO Syndrome: A Systematic Review of 72 Cases

作者：Patrick Fazeli, Saeed Bahramian, Kimia Farahmand, H. Ghoshouni, Yalda Farahmand, Amirali Soheili, Leyla Bagheri, Huria Memari, Aydin Feyzi, Seyed Mohammad Vahabi · 发表于：ACR Open Rheumatology · 年份：2025 · DOI：10.1002/acr2.70101 · 被引用次数：11 · 研究领域：Medicine

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome usually involves bones, joints, and skin. Due to a lack of known pathogenesis and clinical trials, there is no standard treatment of SAPHO syndrome. Because none of the current treatments have a high efficacy and the risk of relapse is high, new treatment options for SAPHO syndrome are necessary. JAK inhibitors (JAK‐I) are a group of small‐molecule drugs with a wide range of effects on inflammatory and autoimmune pathways.